BCG020 / Biocytogen - LARVOL DELTA

BCG020, a novel bispecific antibody targeting EGFR and CD70, is effective against EGFR and CD70 high expressed tumors (AACR 2024) - "We observed that BCG020 treatment (10 mg/kg) potently inhibited growth of EGFR+CD70+ tumors. Taken together, these data indicate that BCG020 is a first-in-class bispecific antibody with potential to treat solid tumors with high expression of EGFR and CD70."

IO biomarker • Oncology • Solid Tumor • CD27 • CD70 • EGFR